UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2017

PIERIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada (State of Incorporation) 001-37471 (Commission File Number) EIN 30-0784346 (IRS Employer Identification No.)

255 State Street, 9th Floor Boston, MA 02109 United States (Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: 857-246-8998

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Derecommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Attached hereto as Exhibit 99.1 and incorporated by reference herein is a corporate presentation of Pieris Pharmaceuticals, Inc.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including the exhibits attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 Corporate Presentation of Pieris Pharmaceuticals, Inc., dated January 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 9, 2017

PIERIS PHARMACEUTICALS, INC.

/s/ Darlene Deptula-Hicks By: Darlene Deptula-Hicks SVP and Chief Financial Officer Name:

Title:

EXHIBIT INDEX

Exhibit No.Description99.1Corporate Presentation of Pieris Pharmaceuticals, Inc., dated January 2017.



Pieris Pharmaceuticals, Inc. Nasdaq:PIRS

Corporate Presentation January 2017

Forward Looking Statements



Statements in this presentation that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. In some cases, you can identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include, without limitation, risks relating to the results of our research and development activities, including uncertainties relating to the discovery of potential drug candidates and the preclinical and clinical testing of our drug candidates; the early stage of our drug candidates presently under development; our ability to obtain and, if obtained, maintain regulatory approval of our current drug candidates and any of our other future drug candidates; our need for substantial additional funds in order to continue our operations and the uncertainty of whether we will be able to obtain the funding we need; our future financial performance; our ability to retain or hire key scientific or management personnel; our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights; our dependence on third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators; our ability to successfully market and sell our drug candidates in the future as needed; the size and growth of the potential markets for any of our approved drug candidates, and the rate and degree of market acceptance of any of our approved drug candidates; developments and projections relating to our competitors and our industry; our ability to establish collaborations; our expectations regarding the time which we will be an emerging growth company under the JOBS Act; our use of proceeds from this offering; regulatory developments in the U.S. and foreign countries; and other factors that are described more fully in our Annual Report on form 10-K filed with the SEC on March 23, 2016. In light of these risks, uncertainties and assumptions, the forward-looking statements regarding future events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements included in this presentation speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

Expanding the Playing Field for Therapeutic Proteins



Novel Drug	Anticalins [®] – A Novel Therapeutic Protein Drug Class				
Novel Drug Class	Fully proprietary and unique				
	 Excellent drug-like properties and clinical validation 				
	Multiple Paths for Success & Risk Diversification				
Novel Modes of Action	 Potentially transformative immuno-oncology (IO) multispecifics 				
	 TME-targeted T cell agonists / Multi-checkpoint blockade 				
	 Inhalation – a topical approach to asthma may bring enormous benefits 				
Validation	Partnerships and Capital to Pursue Clinical-based Inflection Points				
and Growth Capital	 Transformative IO partnership with Servier brings significant upfront payment, fully retained US rights on several novel multispecific drug candidates 				
	\$2.5 B in biodollar potential across Large Pharma partnerships + royalties				
	 \$60+ million in cash on hand after Servier upfront provides runway into 2019 through key value inflection points on fully proprietary pipeline 				
	 PRS-343 (IO): first-in-patient trial initiation 1H17; PRS-060 (asthma): first-in- man trial initiation mid '17; PRS-080 (anemia): multi-dose trial read-out (hemoglobin) 2H17 				
	Roche Sankyo SANOFI				
Non-Confidential					

Servier Immuno-Oncology Partnership pierisis a Transformative Strategic Alliance

Strategic Alliance Highlights



- IO co-development alliance with ~\$30M upfront, up to \$1.8B in potential milestones and low double-digit royalties
- 5 committed IO bispecifics, including PRS-332 (PD-1-based bispecific)
 - Potential to expand to 3 additional bispecific programs
 - Retained co-development and full US commercial rights on PRS-332 and up to 3 additional programs
- A "True Partnership" equal voice with a collaborator having a shared strategic vision and resources to develop several novel IO bispecifics

Strategic Implications of Partnership

- Underscores the value of Pieris' powerful multispecifics platform in IO
- Strengthens cash position to fund development of proprietary product pipeline, while extending financial runway into 2019, through several clinical-stage value inflection points
- Fully retained rights on lead IO bispecific, PRS-343 (4-1BB/HER2), and ability to enter into additional partnerships

Diversified Immuno-Oncology (IO) and Non-IO Product Pipeline



IMMUNO-ONCOLOGY PROGRAMS

Candidate	Target	Indication	Partner	Our Commercial Rights	Discovery	Preclinical	IND- enabling	Phase I	Phase Ib/Ila
PRS-343	4-1BB/HER2 Bispecific	ю		Worldwide					
PRS-342	4-18B/GPC3 Bispecific	ю		Worldwide					
PRS-300s	n.d.	ю		Worldwide					
PRS-332	PD-1/n.d. Bispecific	ю	* A	U.S.					
Servier 4 Programs	n.d./n.d. Bispecific	ю	*	U.S. / Milestones & Royalties					
Roche	n.d.	ю	Roche	Milestones & Royalties					


RESPIRATORY, ANEMIA AND OTHER DISEASE AREAS

Candidate	Target	Indication	Partner	Our Commercial Rights	Discovery	Preclinical	IND- enabling	Phase I	Phase Ib/IIa
PRS-080	Hepcidin	Anemia		Worldwide					
PRS-060	IL4Ra	Asthma		Worldwide					
DS-9001	PCSK9	Dyslipidemia	Daticle Sankyo	Milestones & Royalties					
Daiichi Sankyo	n.d.	n.d.	Duichi-Sankyo	Milestones & Royalties					
Sanofi	P. aeruginosa	Infectious disease	SANOFI	Milestones & Royalties					
PRS-110	cMet	Oncology	Zydus	Major Markets					

Non-Confidential


Entering an Acceleration Phase






Anticalin® Drug Class Origins





3 of 12 human lipocalins and endogenous ligands



- Anticalins[®] are recombinantly engineered human lipocalins
 - Lipocalins are non-immunogenic, extracellular binding proteins
 - Lipocalins have very low sequence identity, yet structural conservation among the 12 known human members is the foundation of the scaffold
- Monomeric, stable, low molecular weight (~18 kDa)
- Phage display-based drug discovery platform

Overlay of several lipocalin X-ray structures


Anticalins[®] Share Several Features with mAbs yet are Highly Differentiated

- Monoclonal Antibodies (mAbs) are highly successful drugs
- Anticalins share many of the beneficial properties of mAbs yet are highly differentiated


Differentiat	Antibody	Anticalin	
Human-derived			
Natural binding molecule	\checkmark	\checkmark	
Non-immunogenic	\checkmark	\checkmark	
High affinity and specificity	\checkmark	\checkmark	
Systemic delivery	\checkmark	\checkmark	
Tunable pharmacokinetics	(√)	\checkmark	
Valent- and geometry-versatil		\checkmark	
Inhalable		\checkmark	
Protein class exclusivity		\checkmark	
Positive freedom to operate la		\checkmark	
Safety Related Efficacy Related IP Relat			P Related
Non-Confidential			8

Valent- and Geometry-Versatile Multispecifics to Achieve Optimal Biology





Potent Multi-target Engagement | Novel MoA | Excellent Drug-like Properties



Anticalins® in Immuno-Oncology

Differentiation Through Unique Multispecific Formats

Next-Generation I-O Therapy Strategy


- Engage immune costimulatory targets in highly novel, targeted manner with unique multispecifics, led by PRS-343 (wholly owned by Pieris)
 - Establish superior therapeutic window over mAbs
 - Improve on benefits of leading checkpoint antagonists and other therapies
- Simultaneously block multiple immune checkpoints in one drug built on key backbone components (e.g. PD-1), led by PRS-332 (partnered with Servier)
 - Demonstrate superiority to existing PD-1 mAbs
 - Exploit independent and fully proprietary PD-1 position
- Demonstrate intra-pipeline synergy between targeted costimulatory engagement and multi-checkpoint blockade within own pipeline
 - 4-1BB (CD137) activation combined with PD-1 blockade expected to result in greater tumor growth inhibition than either monotherapy in preclinical studies¹

Next-Generation IO Therapies:

Novel multispecifics, novel combinations, wholly owned


¹ Shindo, Y et al., Anticancer Res. 2015 Jan;35(1):129-36

Lead IO Program (PRS-343) Addresses _pieris-Biology Challenging for Antibodies Alone




PRS-343 is a First-in-Class TMEactivated Co-stim Agonist














PRS-343 Shows Bifunctional Activity – Dose-dependent Tumor Growth Inhibition & CD8(+)TIL Expansion in SK-OV-3 Model



pieris



PRS-343: IND Enabling Activities on pieris-**Track to Support a FIM in H1 2017**



 HER2 Patient Populations unresponsive to or relapsed from standard of care

Straightforward Registration Path

Manageable trial size and duration with clear endpoints



Non-Confidential

PRS-343: Summary and Milestones



Differentiated profile vs HER2- and 4-1BB-directed benchmark mAbs

- PRS-343 has dual functionality based on monospecific HER2-targeting and bispecific, tumorlocalized costimulation of 4-1BB.
 - Potential for synergistic anti-tumor activity
 - Anti-HER2 mediated tumor growth inhibition
 - 4-1BB-mediated anti-tumor T cell activation
 - Potential to avoid undesirable peripheral T cell activation (reduced systemic side effects)


Excellent drug-like properties


- Antibody-like half-life in mice and cynomolgus monkey
- Low immunogenicity risk (ex vivo Lonza Epibase® test)
- High titers at GMP stage (1000L) and excellent stability

Near-term clinical-stage milestones

- First-in-patient clinical trial initiation planned for 1H17
 - HER2+ solid tumor patients unresponsive to SOC
- · Data-driven focus on high unmet need tumors, e.g. gastric, bladder and breast
- Combination trial with PD-1 mAb planned for 2018








Anticalins in Anemia and Asthma


PRS-080 Potently Neutralizes Hepcidin, ______ The Master Regulator of Iron Metabolism

- Hepcidin is a peptide hormone that serves as a key regulator of iron metabolism by regulating iron entry into plasma from the three main sources of iron:
 - Dietary absorption in the duodenum
 - Release of recycled iron from macrophages
 - Release of stored iron from hepatocytes
- Chronic inflammation drives increased hepcidin production
 - Prevents transferrin-mediated transport to the bone marrow for erythropoiesis
 - Causes anemia of chronic disease
 - "functional" iron deficiency (FID) vs absolute iron deficient anemia
- PRS-080 is a pegylated Anticalin that binds with high affinity and neutralizes Hepcidin



Haematologica 2013 98:11

PRS-080 Drives Iron Mobilization in Healthy Subjects; Ongoing Development -Pierisin FID ESRD Patients




- First Anticalin projected to achieve clinical Proof of Concept (increased hemoglobin)
- Will address FID anemia patients poorly responsive to ESAs and iron therapies
 - Within ESRD, among highest economic burden patient population
 - Est. 90k patients in the US and 80k patients in JP
 - Significant Commercial opportunity


Non-Confidential

🕇 = report data


PRS-060: First-in-Class Inhaled IL4Ra Antagonist For Uncontrolled Asthma




PRS-060 inhibits IL4Ramediated inflammation *in vivo*



- First inhaled biologic to potently engage highly validated asthma target (IL4Ra)
 - IL4Ra is a critical target in uncontrolled asthma
 - Target engagement on lung tissue is a key differentiator over SQ injected mAbs
 - Potential low-dose, low-COGs alternative to mAbs
- Preclinical In-vivo POC for pulmonary delivery
- Formulability for pulmonary delivery





Corporate – Financials – Goals – Accomplishments

Expanding the Playing Field for Therapeutic Proteins



Nous Drus	Anticalins [®] – A Novel Therapeutic Protein Drug Class				
Novel Drug Class	Fully proprietary and unique				
	 Excellent drug-like properties and clinical validation 				
	Multiple Paths for Success & Risk Diversification				
Novel Modes of Action	 Potentially transformative immuno-oncology (IO) multispecifics 				
	 TME-targeted T cell agonists / Multi-checkpoint blockade 				
	 Inhalation – a topical approach to asthma may bring enormous benefits 				
Validation	Partnerships and Capital to Pursue Clinical-based Inflection Points				
and Growth Capital	 Transformative IO partnership with Servier brings significant upfront payment, fully retained US rights on several novel multispecific drug candidates 				
	 \$2.5 B in biodollar potential across Large Pharma partnerships + royalties 				
	 \$60+ million in cash on hand after Servier upfront provides runway into 2019 through key value inflection points on fully proprietary pipeline 				
	 PRS-343 (IO): first-in-patient trial initiation 1H17; PRS-060 (asthma): first-in- man trial initiation mid '17; PRS-080 (anemia): multi-dose trial read-out (hemoglobin) 2H17 				
	Roche Sakyo SANOFI				
Non-Confidential	2				

Management and Board Profile



Senior Management Team



Stephen Yoder, J.D. President & CEO

morphosys



Louis Matis, M.D. SVP, Chief Development Officer

CGI Pharmaceuticals

NIH) NATIONAL CANCER INSTITUTE



Darlene Deptula-Hicks SVP, Chief Financial Officer MICROLINE.



Claude Knopf SVP, Chief Business Officer Baxalta

Board of Directors

Stephen Yoder President & CEO

Non-Confidential

Chau Khuong (Chairman) Partner, OrbiMed Advisors Michael Richman CEO, NextCure, Inc. Amplimune, Chiron, MedImmune, Macrogenics

Steven Prelack SVP, COO, VetCor Velquest Corp., Galectin Therapeutics, BioVex Group Jean-Pierre Bizzari, M.D.

Director Celgene, Servier, Rhone-Poulenc, Sanofi-Aventis

Julian Adams, PH.D. Director Infinity, Millennium Pharm., LeukoSite Inc. Christopher Kiritsy CEO, Arisaph Pharmaceuticals Kos Pharmaceuticals

Financial Highlights – As of 9/30/16



Cash & Cash Equivalents*	\$36.6M
Total Debt	\$0.0M
Revenue Since Inception (license & collaborations)	\$54.0M
Grant Revenue Since Inception	\$14.2M
9 Months 2016 Net Loss	(\$16.2M)
9 Months 2016 Cash Burn (less cash received from PIPE financing & Roche Up Front payment)	\$14.5M
Common Shares Outstanding	43.1M
Preferred Shares Outstanding (as converted)	4.9M
Options Outstanding	4.8M

* Does not include upfront payment of ~\$ 31.3M from Servier collaboration

Non-Confidential

2016 Achievements and 2017 Expected Milestones



2016: Significant Achievements

Immuno-Oncology

- Generated our first PD-1 based bispecific (PRS-332)
- In vivo POC for 4-1BB bispecific immune costimulatory (PRS-343)
- Progressing PRS-343 trough IND-enabling studies

Respiratory

 PRS-060 (asthma) through IND-enabling studies

Anemia

 Conducting first-in-patient study for PRS-080 in targeted patient population (FID in ESRD)

2017: a Year of Transformation

Immuno-Oncology

- Cornerstone IO Servier Strategic Alliance including PRS-332. Financial runway into 2019 and leaves PRS-343 unencumbered
- PRS 343: First-in-patient clinical trial initiation planned for 1H17
- Several preclinical-stage, highly differentiated multispecifics

Respiratory

PRS-060: Initiation of First-in-patient trial Mid-2017

Anemia

- PRS-080
 - Phase 1b results disclosure by end of Q2 2017
 - Phase 2a results 2H 2017





Pieris Pharmaceuticals, Inc.

255 State Street, 9th Floor Boston, MA 02109 USA <u>info@pieris.com</u> <u>www.pieris.com</u>